Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
18 papers
Recent·Most cited
H. M. Parrington, N. Kose, E. Armstrong, L. S. Handal, S. Diaz, J. X. Reidy, J. Dong, G. B. E. Stewart-Jones, P. Shrivastava-Ranjan, S. Jain, C. G. Albarino, R. H. Carnahan, J. E. Crowe
The paper identifies potent human monoclonal antibodies against Sosuga virus, revealing epitope diversity and neutralization mechanisms.
bioRxiv · Nov 17, 2022Immunology
E. C. Chen, P. Gilchuk, S. J. Zost, P. A. Ilinykh, E. Binshtein, K. Huang, L. Myers, S. Bonissone, S. Day, C. R. Kona, A. Trivette, J. X. Reidy, R. E. Sutton, C. Gainza, S. Monroig, , J. E. Crowe
The paper analyzes the human antibody response to ebolavirus glycoprotein, identifying public clonotypes with neutralizing activity and implications for vaccine design.
bioRxiv · Jan 12, 2022 · PreprintImmunology
N. Suryadevara, A. Shiakolas, L. VanBlargan, E. Binshtein, R. Chen, J. B. Case, K. Kramer, E. Armstrong, L. Myers, A. Trivette, C. Gainza, R. Nargi, C. Selverian, E. Davidson, B. Doranz, , J. E. Crowe
The paper identifies a rare antibody that targets the SARS-CoV-2 spike trimer interface, disrupting viral entry and providing protection in mice.
bioRxiv · Jan 12, 2022Immunology
N. Raju, X. Zhan, S. Das, L. Karwal, H. Dean, J. E. Crowe, R. H. Carnahan, I. Georgiev
This study presents a computational framework to analyze neutralizing antibody specificities in response to dengue vaccines, revealing differences in immune responses based on prior infection status.
bioRxiv · Dec 2, 2021Immunology
R. R. Cobb, J. Nkolola, P. Gilchuk, A. Chandrashekar, R. V. House, C. G. Earnhart, N. M. Dorsey, S. A. Hopkins, D. M. Snow, R. E. Chen, L. A. VanBlargan, M. Hechenblaickner, B. Hoppe, L. Collins, M. T. Tomic, , J. E. Crowe
This study shows that a combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques and neutralizes variants of concern in vitro.
bioRxiv · Sep 27, 2021 · PreprintImmunology
K. J. Kramer, E. M. Wilfong, K. Voss, S. Barone, A. R. Shiakolas, N. Raju, C. E. Roe, N. Suryadevara, L. M. Walker, S. C. Wall, A. Paulo, S. Schaefer, D. Dahunsi, C. S. Westlake, J. E. Crowe, , J. M. Irish
bioRxiv · Jul 28, 2021Immunology
A. R. Shiakolas, N. Johnson, K. J. Kramer, N. Suryadevara, D. Wrapp, S. Periasamy, K. A. Pilewski, N. Raju, R. Nargi, R. E. Sutton, L. Walker, I. Setliff, J. E. Crowe, A. Bukreyev, R. H. Carnahan, , I. S. Georgiev
This study demonstrates that integrating ligand blocking into LIBRA-seq improves the efficiency of identifying potent SARS-CoV-2 neutralizing antibodies.
bioRxiv · Jun 2, 2021 · PreprintImmunology
K. J. Kramer, N. V. Johnson, A. R. Shiakolas, N. Suryadevara, S. Periasamy, N. Raju, J. K. Williams, D. Wrapp, S. J. Zost, C. M. Holt, C.-L. Hsieh, R. E. Sutton, A. Paulo, E. Davidson, B. J. Doranz, , I. S. Georgiev
This study identifies a potent SARS-CoV-2 antibody, 54042-4, that neutralizes variants of concern and has a unique epitope and genetic structure.
bioRxiv · May 16, 2021Immunology
E. C. Chen, P. Gilchuk, S. J. Zost, N. Suryadevara, E. S. Winkler, C. R. Cabel, E. Binshtein, R. E. Sutton, J. L. Rodriguez, S. Day, L. Myers, A. Trivette, J. K. Williams, E. Davidson, S. Li, , J. E. Crowe
The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.
bioRxiv · May 2, 2021Immunology
P. Gilchuk, C. D. Murin, R. W. Cross, P. A. Ilinykh, K. Huang, N. Kuzmina, V. Borisevich, K. N. Agans, J. B. Geisbert, R. H. Carnahan, R. S. Nargi, R. E. Sutton, N. Suryadevara, S. J. Zost, R. G. Bombardi, , J. E. Crowe
This paper develops a therapeutic cocktail of two human antibodies that protect against multiple ebolaviruses in non-human primates and reveals their molecular mechanisms.
bioRxiv · May 2, 2021 · PreprintImmunology
N. Suryadevara, S. Shrihari, P. Gilchuk, L. VanBlargan, E. Binshtein, S. Zost, R. Nargi, R. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. Doranz, R. H. Carnahan, L. Thackray, , J. E. Crowe
The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.
bioRxiv · Jan 19, 2021Immunology
S. J. Zost, J. Dong, I. M. Gilchuk, P. Gilchuk, N. J. Thornburg, S. Bangaru, N. Kose, J. A. Finn, R. Bombardi, C. Soto, R. S. Nargi, R. P. Irving, N. Suryadevara, J. B. Westover, R. H. Carnahan, , J. E. Crowe
The paper identifies common genetic and structural features of human antibodies recognizing the influenza HA trimer interface, suggesting it as a target for vaccine design.
bioRxiv · Dec 31, 2020Immunology
E. S. Winkler, P. Gilchuk, J. Yu, A. L. Bailey, R. E. Chen, S. J. Zost, H. Jang, Y. Huang, J. D. Allen, J. B. Case, R. E. Sutton, R. H. Carnahan, T. L. Darling, A. C. M. Boon, M. Mack, , M. Diamond
This study shows that neutralizing antibodies against SARS-CoV-2 need intact Fc functions and monocytes for optimal therapeutic protection in animal models.
bioRxiv · Dec 28, 2020Immunology
A. R. Shiakolas, K. J. Kramer, D. Wrapp, S. I. Richardson, A. Schäfer, S. Wall, N. Wang, K. Janowska, K. A. Pilewski, R. Venkat, R. Parks, N. P. Manamela, N. Raju, E. Friedman Fechter, C. M. Holt, , I. S. Georgiev
The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.
bioRxiv · Dec 20, 2020 · PreprintImmunology
A. J. Greaney, T. N. Starr, P. Gilchuk, S. J. Zost, E. Binshtein, A. N. Loes, S. K. Hilton, J. Huddleston, R. Eguia, K. H. Crawford, A. S. Dingens, R. S. Nargi, R. E. Sutton, N. Suryadevara, P. W. Rothlauf, , J. D. Bloom
This study maps mutations in the SARS-CoV-2 spike RBD that escape antibody recognition, revealing escape mutation patterns and enabling the design of antibody cocktails.
bioRxiv · Sep 10, 2020Microbiology
S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, , J. E. Crowe
The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.
bioRxiv · May 22, 2020Immunology
P. Gilchuk, R. G. Bombardi, J. H. Erasmus, Q. Tan, R. S. Nargi, C. Soto, P. Abbink, T. J. Suscovich, L. A. Dunellin, A. Khandhar, J. Archer, J. Liang, M. E. Fouch, E. Davidson, B. Doranz, , R. H. Carnahan
This study develops an integrated platform to rapidly discover and validate potent antiviral human monoclonal antibodies against Zika virus.
bioRxiv · May 12, 2020Immunology
S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe
This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.
bioRxiv · May 12, 2020Immunology